Alsalmi, O.A.; Aljohani, A.I.; Almutairi, S.M.; Alsufyani, R.O.; Alrubayee, A.R.; Alzahrani, K.J.; Alkhammash, G.E.; Aljuaid, H.M.; Alghamdi, H.S.; Alsaeedi, F.A.
Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer. Genes 2025, 16, 302.
https://doi.org/10.3390/genes16030302
AMA Style
Alsalmi OA, Aljohani AI, Almutairi SM, Alsufyani RO, Alrubayee AR, Alzahrani KJ, Alkhammash GE, Aljuaid HM, Alghamdi HS, Alsaeedi FA.
Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer. Genes. 2025; 16(3):302.
https://doi.org/10.3390/genes16030302
Chicago/Turabian Style
Alsalmi, Ohud A., Abrar I. Aljohani, Shahad M. Almutairi, Rana O. Alsufyani, Abdulrahman R. Alrubayee, Khalid J. Alzahrani, Ghaida E. Alkhammash, Hessa M. Aljuaid, Hanan S. Alghamdi, and Fouzeyyah A. Alsaeedi.
2025. "Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer" Genes 16, no. 3: 302.
https://doi.org/10.3390/genes16030302
APA Style
Alsalmi, O. A., Aljohani, A. I., Almutairi, S. M., Alsufyani, R. O., Alrubayee, A. R., Alzahrani, K. J., Alkhammash, G. E., Aljuaid, H. M., Alghamdi, H. S., & Alsaeedi, F. A.
(2025). Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer. Genes, 16(3), 302.
https://doi.org/10.3390/genes16030302